DIPP Study

DIPP Study
Name	DIPP Study
Established	1994
Location	Finland
Focus	Type 1 diabetes, autoimmune biomarkers, pediatric epidemiology
Founders	Jorma Ilonen, Mikael Knip

DIPP Study

The DIPP Study was a large-scale prospective cohort investigation begun in the 1990s to investigate genetic, immunological, and environmental determinants of Type 1 diabetes in children. Initiated in Finland by investigators associated with institutions such as the University of Tampere, the project sought to identify preclinical markers, natural history, and potential windows for prevention. The program interconnected clinical centers, laboratory networks, and public health registries including partnerships with groups like The Finnish Diabetes Association and international collaborators such as the World Health Organization and International Society for Pediatric and Adolescent Diabetes.

Background and Objectives

The study emerged amid rising incidence of Type 1 diabetes observed in epidemiological reports by organizations including World Health Organization surveillance and national registries in Finland and across Europe. Founders including Mikael Knip and Jorma Ilonen aimed to map relationships among human leukocyte antigen genotypes, seroconversion to islet autoantibodies, and progression to clinical diabetes. Objectives included establishing longitudinal cohorts, characterizing natural history comparable to cohorts like the TEDDY Study and the DAISY Study, and informing trials similar to the TRIGR trial and immunointervention strategies related to agents evaluated in protocols influenced by National Institutes of Health priorities.

Study Design and Methods

DIPP employed a prospective newborn screening framework combined with serial follow-up. Newborns were genotyped for susceptibility alleles at the HLA region, notably haplotypes analogous to those studied in investigations from institutions such as Karolinska Institutet and University of Oulu. Children meeting genetic risk thresholds were enrolled for periodic sampling for islet autoantibodies (including insulin autoantibodies measured with assays refined in collaboration with reference labs at University of Cambridge and University of Bristol). The design incorporated standardized case definitions adopted by consortia like the International Diabetes Federation and leveraged statistical methods previously applied in cohort analyses by teams at Harvard School of Public Health and Karolinska Institutet.

Participant Recruitment and Cohorts

Recruitment occurred through neonatal screening in regions served by pediatric centers in Tampere, Oulu, and Turku, enrolling thousands of infants identified by HLA risk alleles comparable to those characterized at the University of Helsinki. Cohorts included high-risk infants, nested case-control samples, and subcohorts eligible for intervention trials analogous to those organized by the TrialNet network. Participants were followed with regular clinic visits coordinated with pediatric endocrinology units at hospitals such as Tampere University Hospital and community health services connected to Social Insurance Institution of Finland registries.

Key Findings and Outcomes

DIPP produced landmark observations about timing and sequence of seroconversion to autoantibodies (for example, insulin autoantibody appearing early compared with glutamic acid decarboxylase autoantibody), mirroring findings from contemporaneous studies at Barbara Davis Center and Karolinska University Hospital. The project clarified rates of progression from multiple autoantibodies to clinical Type 1 diabetes and identified age-related incidence peaks consistent with data from the SEARCH for Diabetes in Youth Study and national surveillance by Finnish Institute for Health and Welfare. Publications from DIPP influenced risk stratification frameworks used by consortia like TrialNet and informed prevention trial design similar to protocols at Steno Diabetes Center and Eli Lilly and Company sponsored research.

Biomarkers and Laboratory Analyses

Laboratory work centered on high-sensitivity assays for islet autoantibodies (including insulin, GAD65, IA-2) developed in coordination with reference laboratories at University of Oxford and Erasmus MC. Genetic analyses targeted HLA class II alleles and non-HLA loci characterized in genome-wide studies conducted by consortia such as the Wellcome Trust Case Control Consortium and groups at Broad Institute. Metabolomic and environmental exposure assessments incorporated techniques comparable to those used by teams at Massachusetts General Hospital and Karolinska Institutet, enabling analyses linking viral exposures (for example enteroviruses studied in collaboration with virology groups at University of Copenhagen) to seroconversion events.

Impact and Subsequent Research

The DIPP Study shaped screening strategies, contributed to international pooled analyses with cohorts like the TEDDY Study, and underpinned rationale for preventive immunotherapy trials analogous to TrialNet antigen-specific immunotherapy. Its data informed policy discussions involving agencies such as the European Commission and national health institutes, and guided translational projects at centers like University of Cambridge and Yale School of Medicine. Follow-on research built on DIPP datasets for genetic epidemiology, biomarker discovery, and mechanistic studies pursued at institutions including the Wellcome Sanger Institute and University College London. The legacy of DIPP endures in collaborative networks, improved risk prediction algorithms, and continued efforts toward primary prevention of Type 1 diabetes.

Category:Type 1 diabetes studies